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Abstract
Background: Recent evidence suggests that the commensal microbes act as a barrier against invading pathogens
and enteric infections are the consequences of multi-layered interactions among commensals, pathogens, and the
host intestinal tissue. However, it remains unclear how perturbations of the gut microbiota compromise host
infection resistance, especially through changes at species and metabolite levels.
Results: Here, we illustrate how Bacteroides vulgatus, a dominant species of the Bacteroidetes phylum in mouse
intestine, suppresses infection by Vibrio cholerae, an important human pathogen. Clindamycin (CL) is an antibiotic that
selectively kills anaerobic bacteria, and accordingly Bacteroidetes are completely eradicated from CL-treated mouse
intestines. The Bacteroidetes-depleted adult mice developed severe cholera-like symptoms, when infected with
V. cholerae. Germ-free mice mono-associated with B. vulgatus became resistant to V. cholerae infection. Levels of V.
cholerae growth-inhibitory metabolites including short-chain fatty acids plummeted upon CL treatment, while
levels of compounds that enhance V. cholerae proliferation were elevated. Furthermore, the intestinal
colonization process of V. cholerae was well-simulated in CL-treated adult mice.
Conclusions: Overall, we provide insights into how a symbiotic microbe and a pathogenic intruder interact
inside host intestine. We identified B. vulgatus as an indigenous microbial species that can suppress intestinal
infection. Our results also demonstrate that commensal-derived metabolites are a critical determinant for host
resistance against V. cholerae infection, and that CL pretreatment of adult mice generates a simple yet useful
model of cholera infection.
Keywords: Vibrio cholerae, Gut microbiota, Colonization resistance, Short-chain fatty acids, Metabolomics,
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Background
Vibrio cholerae is the causative agent of pandemic diarrheal
disease, cholera. While cholera toxin (CT) and toxin-
coregulated pilus (TCP) are known to be the major
virulence determinants, its pathogenic mechanisms are
starting to be understood as consequences of interaction
with indigenous microbes, collectively termed gut
microbiota [1–4]. A key feature of the gut microbiota
is its protective capacity against enteropathogenic
infections, termed “colonization resistance” [5–7]. This
property can be ascribed to the microbial ecosystem
that is formed within the host intestine. This microbial
ecosystem is an ever-changing community of various
microbial species regulated by a complex network of
microbiota-intrinsic and microbiota-extrinsic factors [8].
Microbiota-intrinsic factors such as interactions
between the gut-residing species serve as the primary
determinant of community composition. Such interac-
tions include interbacterial niche competition [9] and
secretion of antimicrobial substances [10]. For example,
Bacteroides species that reside in the human gut, such as
Bacteroides fragilis and Bacteroides uniformis, utilise
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membrane attack complex/perforin toxins BSAP-1 and
BSAP-2 for intraspecies antagonism [11]. Microbiota-ex-
trinsic factors include inflammation, diet, and antibiotic
treatment. However, the aforementioned microbiota-in-
trinsic and extrinsic factors do not operate in exclusion of
another. For example, compositional shift induced by an
external factor may, in turn, modulate the host immune
response via production of specific metabolites [8].
Recent studies have demonstrated that antibiotic
treatments alter the gut microbiota in humans and
other mammals [12–15], and increase the susceptibility
of the host to infections by various enteric pathogens
such as Shigella flexneri [16], Salmonella enterica [17],
Clostridium difficile [18, 19], and vancomycin-resistant
Enterococcus [20]. The abolishing effect of antibiotic
treatment on host resistance to infection is most likely
implemented through a multitude of factors, including
suppression of specific microbial species, alteration of
the metabolomic landscape as a result of the changed
microbiome composition, and/or host responses [21–23].
These findings prompted us to investigate the effects
of different classes of antibiotics on the gut microbiota
and how they relate to host resistance against V. cho-
lerae infection.
In this study, we uncover a unique microbiota-ex-
trinsic treatment that induces severe cholera-like
symptoms in adult mice, that are otherwise completely
resistant. Furthermore, we show that a dramatic shift
in metabolome production profile accounts for the
compromised infection resistance in the host. This re-
port highlights the importance of commensal-derived
metabolites as a crucial determinant of host suscepti-
bility to enteric infection.
Results
Clindamycin-treated adult mice exhibited dramatic gut
microbiota compositional changes and became
susceptible to V. cholerae infection
Colonization of enteric pathogens occurs depending
on the composition of indigenous microbes inside the
host intestine [5, 24, 25]. In order to observe the ef-
fects of gut microbiota compositional changes on host
infection resistance under diverse experimental condi-
tions, we treated adult C57BL/6 specific pathogen-free
(SPF) mice (8 weeks of age) with three different antibi-
otics that have a distinct mode of bacterial killing;
streptomycin (SM), vancomycin (VAN), and clindamy-
cin (CL). SM is a broad-spectrum antibiotic that tar-
gets both Gram-positive and Gram-negative bacteria.
VAN is an effective antibiotic against Gram-positives
[26], while CL is known to selectively kill anaerobes
[27, 28]. After daily treatment for 5 days, mouse feces
were collected to analyze microbiota composition by
16S rRNA gene sequencing. Five bacterial phyla were
found to have characteristic distributions among
groups (Fig. 1a–d). In the untreated control group,
Bacteroidetes was the most abundant phylum and the
members of that single phylum occupied approximately
80% of the entire microbiota population (Fig. 1a). Upon
SM treatment, the Verrucomicrobia phylum emerged,
while the Bacteroidetes phylum maintained its pre-
dominant occupancy (Fig. 1b). VAN treatment resulted
in multiplication of bacterial cells belonging to the
Verrucomicrobia and Proteobacteria phyla, both of
which are Gram-negatives (Fig. 1c). As a result of CL
treatment, the Bacteroidetes phylum was eradicated,
while the Firmicutes phylum remained largely un-
changed in number (Fig. 1d). This observation is con-
sistent with previous findings that CL is effective in
treating infections of Bacteroides fragilis, a major spe-
cies of the Bacteroidetes phylum [29, 30]. On the other
hand, the Proteobacteria phylum underwent explosive
expansion during CL treatment, further demonstrating
that CL is not effective in inhibiting the growth of
facultative anaerobes (Fig. 1d).
Subsequently, the mice of each antibiotic group were
infected with 5 × 108 CFU of the V. cholerae 7th
pandemic strain, N16961, to monitor susceptibility to
infection and infection-induced microbiota compos-
ition changes. In the control and SM-treated groups,
microbiota composition did not change much follow-
ing V. cholerae infection (Fig. 1e, f). In response to
N16961 infection, the relative abundance of the
Bacteroidetes phylum increased in the VAN-pretreated
group (Fig. 1g vs. c). In CL-treated mice, the relative
abundance of the Firmicutes phylum increased, while
that of the Proteobacteria phylum decreased in re-
sponse to V. cholerae infection (Fig. 1h). Importantly,
among the Proteobacteria phylum detected in Fig. 1h,
~ 8.81% was found to be derived from V. cholerae-spe-
cific 16S rRNA gene sequence (Fig. 3). This result is
worthy of particular attention because V. cholerae-spe-
cific sequence was not detected in the Proteobacteria
populations in other groups (Fig. 1f, g).
Our results indicate that V. cholerae may actively
colonize the adult mouse intestine under conditions
created by CL treatment. To gain more insight into the
outcomes of V. cholerae infection, we investigated
whether any anatomical change was induced in the
gastrointestinal tract ranging from the small intestine
to the rectum. In the first three experimental groups,
mouse tissues appeared similar to one another and no
major changes were observed following V. cholerae in-
fection (Fig. 1i–k). In contrast, infection-induced phe-
notypes were clearly demonstrated in the CL-treated
group for the following indications (Fig. 1l). First, fluid
accumulation was clearly observed in the small intes-
tine (red arrowheads). Second, the size of the cecum
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was markedly smaller compared to those in other
groups (black arrowhead). Third, the colon appeared
shorter and more interestingly, became transparent,
while the colons in other groups were filled with feces
(dotted line around the colon). Forth, fecal matter dis-
charged from the CL-treated group was highly aqueous
(data not shown). Together, these results demonstrate
that V. cholerae infection induces cholera-like symp-
toms in adult mice, when their gut microbiota compo-
sitions are altered by CL treatment.
CL treatment with a different regimen similarly induced
hypersusceptibility to V. cholerae infection
Our results, shown in Fig. 1, demonstrate that symp-
toms of watery diarrhea observed in human cholera
patients can also be induced in adult mice by a simple
antibiotic pretreatment. In the above experiment, mice
were treated with a mild concentration of CL daily for
5 days. To elucidate whether CL treatment could elicit
similar effects within a shorter period, we conducted
another set of infection experiments with a single treat-
ment of higher CL dosage (Additional file 1: Fig. S1A).
Similar to previous results with lower CL dosage,
significantly increased fluid accumulation (FA) was in-
duced in adult mouse intestine at 24 h post-infection.
The FA ratio was determined to be ~ 0.176, a value ~
1.6-fold higher in comparison to that of the uninfected
group (Additional file 1: Fig. S1B). Consistent with this
finding, robust V. cholerae colonization was observed
in CL-pretreated mice. The number of V. cholerae cells
Fig. 1 Microbial population changes in response to the antibiotic treatments and host responses to V. cholerae infection in each treatment
group. Adult mice were divided into four groups and treated with PBS (a), streptomycin (SM) (b), Vancomycin (VAN) (c), or clindamycin (CL) (d).
Treatments were performed as described in “Methods” section. Fecal matter was collected at the end of the treatment, and microbial DNA was
extracted for 16S rRNA gene amplicon sequencing. Microbial compositions at the phylum level are shown in pie charts. Relative abundance of
each phylum is proportional to the arc length of each slice. Five dominant phyla (i.e., Bacteroidetes, Firmicutes, Verrucomicrobia, Deferribacteres,
and Proteobacteria) numbered from 1 to 5 are indicated with different colors. Following treatment, mice in each group were infected with 5 ×
108 CFU of N16961 cells. At 24 h post-infection, fecal matter collected from each group (e–h) was subject to microbial composition analysis. *The
Proteobacteria phylum shown in panel H includes V. cholerae at 8.81% abundance. At the end of the infection period, mouse gastrointestinal
tracks were extracted from each group to visualize infection-induced phenotypes (i–l). Red arrowheads shown in panel l indicate regions of small
intestine with fluid accumulation, while a black arrowhead shows the cecum, where the size is remarkably smaller than in other mice. Dotted
lines in panels i–l indicate the large intestines
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recovered from the small intestine (SI) or cecum was
remarkably larger in CL-treated vs. control group. V.
cholerae cells of > 109 CFU were grown per gram sam-
ple in SI and cecum, respectively. Likewise, ~ 109 CFU
was also detected in fecal pellets shed from CL-treated
mice (Additional file 1: Fig. S1C). In contrast, V. cho-
lerae cells were not detected at all in feces discharged
from the control group. Given that an infection dosage
of 5 × 108 CFU was used, these results demonstrate
that (i) V. cholerae cells were almost completely elimi-
nated inside the intestine of regular adult mice while
(ii) the same number of inoculated cells was more
highly proliferated in the CL-pretreated adult mouse
intestine.
Germ-free mice transplanted with feces of CL-treated
mice were susceptible to V. cholerae infection
Previous studies have revealed that CL treatment can
modulate the production of pro-inflammatory cytokines,
especially in response to lipopolysaccharide [31–33].
Furthermore, CL at sub-lethal concentrations stimulate
neutrophil phagocytosis in vitro against Staphylococcus
aureus [34] and Bacteroides spp. [35]. While our results
strongly suggest that CL-induced changes in gut
microbiota composition are associated with elevated
susceptibility to V. cholerae infection, these previous
reports also indicate that enhanced V. cholerae infect-
ivity in adult mice might be attributed to CL-induced
modulation of the host immune response. To address
this issue, we conducted fecal microbiota transplant-
ation (FMT) to germ-free (GF) mice and tested
whether the GF mice with reconstituted intestinal
microbiota develop differential resistance to V. cho-
lerae infection. Fecal pellets freshly collected from
PBS- or CL-treated mice were resuspended in PBS and
transferred to GF mice via oral gavage. Following a 3-
day transplant stabilization period, 5 × 108 N16961
cells were infected (Fig. 2a). GF mice transplanted with
PBS-treated control fecal pellets developed strong
resistance to the infection. Viable V. cholerae was re-
covered neither from the SI of all six mice nor from
the cecum isolated from five out of six mice (Fig. 2b).
While varying degrees of N16961 cells were detected
in feces discharged from the GF mice transplanted
Fig. 2 Germ-free mice transplanted with feces of CL-treated mice are susceptible to V. cholerae infection. a Schematic diagram of the
experimental procedure. Germ-free mice (C57BL/6, 8~9 weeks old, n = 6 per group) received fecal suspensions (50 μL) derived from PBS- or CL-
treated SPF mice. Following 3 days of stabilization, transplanted mice were challenged with V. cholerae infection (5 × 108 CFU) for 24 h. b The SI
and cecum were removed from each mouse for tissue homogenization. Fresh fecal matter was collected to prepare fecal suspensions. Aliquots of
lysates or suspensions were serially diluted to count CFU of V. cholerae on LB agar supplemented with 200 μg/mL SM. Values are displayed on a
log scale as mean ± SEM for each group. *P < 0.05 versus bacterial CFU detected in the control group. **P < 0.001 versus bacterial CFUs detected
in the control group. c In a separate set of experiments (n = 3 per group), small intestines were extracted for tissue homogenization, and aliquots
of homogenates were assessed for detection of CT by ELISA. *P < 0.01 versus CT level in the control group
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with control feces, four out of six mice produced feces
that contained ten or fewer N16961 cells per gram
(Fig. 2b). In contrast, N16961 colonization occurred
more actively in the GF mice transplanted with CL-
treated and therefore Bacteroidetes-depleted feces. In
cecum and feces, > 104-fold and > 103.4-fold higher
bacterial colonization were observed, respectively,
compared with the control group (Fig. 2b).
We next asked whether production of CT, a critical
virulence determinant, was accordingly increased
during active V. cholerae colonization. As shown in
Fig. 2c, in response to V. cholerae infection, CT
production was significantly increased in mice trans-
planted with fecal suspensions of CL-treated mice.
Since CL would not be much left in the feces dis-
charged from the CL-treated mice, our results demon-
strate that altered gut microbiota composition induced
by CL treatment is directly responsible for rendering
the murine host more susceptible to V. cholerae
infection.
Bacteroides vulgatus is the predominant species in the
Bacteroidetes phylum and it inhibited V. cholerae growth
in vivo
Based on our results presented in Fig. 1, elevated V.
cholerae infection in CL-pretreated mice could be as-
cribed either to the depletion of the Bacteroidetes or
to the expansion of Proteobacteria phylum. Meanwhile,
we noticed the followings. First, the Proteobacteria
population similarly sufficiently propagated in VAN-
treated mice, a group that did not develop cholera-like
symptoms (Fig. 1c). Second, the relative abundance of
the Bacteroidetes phylum increased from ~ 38% (be-
fore infection) to ~ 61% (after infection) in VAN-
treated mice (Fig. 1c, g). Based on these results, we
postulated that the lack of cholera-like symptoms in
the VAN-treated group was due not only to the pres-
ence of the Bacteroidetes phylum but also to the infec-
tion-induced expansion of its population. We
hypothesized that the Bacteroidetes phylum, which
predominantly occupies the adult mouse intestine,
plays a critical role in protecting its host from V. cho-
lerae infection.
To provide an insight into which bacterial species
are core members of the Bacteroidetes phylum, we
performed a species-level population analysis using
16S rRNA gene sequencing. When necessary, we con-
ducted PCR reactions with species-specific primer sets
and verified the sequences of amplification products
(data not shown). Three distinct bacterial species were
determined to belong to the Bacteroidetes phylum;
Bacteroides vulgatus, Parabacteroides goldsteinii, and
Bacteroides caccae. In control mice, B. vulgatus was
found to be present in the largest quantity, with a
relative abundance greater than 50% of the entire
population (Fig. 3). In response to VAN treatment, P.
goldsteinii propagated, whereas B. vulgatus was dimin-
ished in population size. Of note, however, the relative
abundance of the B. vulgatus population was recovered to
its original level following V. cholerae infection. P. goldstei-
nii has been reclassified from Bacteroides goldsteinii [36]
and a strain isolated from human intestine was resistant
to VAN treatment [37]. As shown in Fig. 1d, l, no 16S
rRNA gene sequences matching any of these three spe-
cies were detected in feces discharged from CL-treated
mice either before or after V. cholerae infection (Fig. 3).
Because B. vulgatus was the most dominant species
in the adult mouse intestine, we next assessed, under a
more defined condition, the effect of B. vulgatus on
altering host susceptibility to V. cholerae infection. To
this end, we mono-associated GF mice with a suspen-
sion of B. vulgatus cells, grown anaerobically in vitro
(Fig. 4a). B. vulgatus colonies cultivated straight from
mouse fecal suspensions were subject to RAPD assay
and an identical amplification pattern was observed
between isolated colonies, thereby leading us to con-
clude that most colonies were clonal (Additional file 2:
Figure S2). As shown in Fig. 4a, GF mice were also
mono-associated with heat-killed B. vulgatus before
being infected with V. cholerae cells as an additional
negative control. At 24 h post-infection, significantly
reduced numbers of V. cholerae cells were recovered
in animals that were mono-associated with live B.
vulgatus. In SI and colon, ~ 830-fold and ~ 40-fold less
V. cholerae colonization were observed, respectively, as
compared with the PBS control group. Likewise, V.
cholerae cell numbers, recovered from feces of the GF
mice transplanted with live B. vulgatus, was ~ 75-fold
lower than the PBS control (Fig. 4b). Importantly, V.
cholerae colonization was never decreased in the
animals mono-associated with heat-inactivated B.
vulgatus cells (Fig. 4b). These results suggest that
active B. vulgatus cells, when present in adult mouse
intestine, can suppress V. cholerae colonization.
We next explored whether B. vulgatus also effectively
inhibits V. cholerae colonization in the infant mouse
model that has been used to study V. cholerae infec-
tion [38, 39]. Five-day-old infant mice were divided
into two groups, with the first group being trans-
planted with B. vulgatus and the other group serving
as a negative control (Fig. 4c). B. vulgatus, when trans-
planted in the intestine of the infant mouse, can also
effectively suppress V. cholerae colonization and fluid
accumulation (Fig. 4d). V. cholerae colonization was
decreased ~ 4.47-fold in the presence of transplanted
B. vulgatus. Although the difference between these two
groups was less pronounced than what was observed in
experiments with adult mice, V. cholerae colonization and
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infection-induced fluid accumulation were both re-
duced significantly in B. vulgatus-transplanted infant
mice (Fig. 4d).
Metabolome profiles revealed the characteristic
metabolites that directly modulate intestinal V. cholerae
growth
We next conducted a metabolome analysis to examine
whether metabolomic profiles are altered in response
to CL treatment and/or V. cholerae infection. We pos-
tulated that alterations of metabolite levels influenced
host susceptibility to V. cholerae infection. Cecal con-
tents were subject to sample preparation for CE-TOF/
MS, as described in the “Methods” section. Among the
metabolites detected in our analysis, a total of 273 me-
tabolites were successfully quantified and their relative
quantities between samples are presented in a heat
map (Fig. 5). A table that lists all 273 metabolites and
their relative amounts in four samples is shown as
supplementary information (a supplementary excel
file). Of the many differences between the metabolo-
mic profiles of each group, the most noticeable one is
that red and green line clusters representing com-
pounds in large and small quantities, respectively, are
generally reversed in control SPF vs. CL-treated group
(column 1 vs. 3, Fig. 5). Such striking alterations in
metabolome profiles can be interpreted as a conse-
quence of the dramatic microbiota compositional
changes, as shown in Fig. 1. Interestingly, a smaller
degree of profile change was observed in response to
V. cholerae infection in both experimental groups (col-
umn 1 vs. 2 and column 3 vs. 4, Fig. 5). These results
demonstrate that (i) CL treatment induces more sub-
stantial changes in metabolome profiles than does V.
Fig. 3 Species-level microbiota populations in response to antibiotic treatments and after V. cholerae infection. Distribution of commensal
microbial species at the phylum (far-left column) and species (second column) levels are presented by colors in 8 different experimental
conditions. Con, SM, VAN, and CL in the first low indicate microbial samples of corresponding antibiotic treatments and Con-Vc, SM-Vc, VAN-Vc,
and CL-Vc indicate samples of the same groups following V. cholerae infection. Three species were determined to belong to Bacteroidetes
(brown) and Proteobacteria (gray) phyla and 17 species belonging to the Firmicutes (orange) phylum were identified. Only bacterial species with
a relative abundance of > % of the total microbiota population were selected and displayed. Relative abundance of each species is indicated by
color-coded boxes. For example, brown boxes mean that the abundance of a given species under a specific condition is > 50%. A complete
elimination of Bacteroides vulgatus is indicated with **, while a pink box denoted by * indicates 8.81% V. cholerae occupancy
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cholerae infection, and (ii) CL-induced changes on me-
tabolite level might have created an environment that
strongly facilitates V. cholerae growth and pathogenesis.
Table 1 shows a list of metabolites that were de-
tected in the greatest quantities in control SPF (com-
pounds 1~13) or CL-treated (compounds 14~27) mice.
Out of the 13 molecules detected in the SPF mouse
ceca, all except for cholic acid were not detected in
CL-treated mice. It is of particular interest that (iso)
butyric acid, propionic acid, and (iso) valeric acid,
collectively termed short-chain fatty acid (SCFA) are
among the most abundantly detected metabolites in
control group (Table 1). Fourteen compounds (14~27),
whose relative quantities are greater than 1.0E-03,
Fig. 4 B. vulgatus inhibits V. cholerae growth in vivo. a Schematic diagram of the experimental procedure. Germ-free mice (C57BL/6, 8~9 weeks
old, n = 3 or 4 per group) ingested 50 μL PBS (n = 3), heat-inactivated (autoclaved) B. vulgatus cell suspension (n = 4), or live B. vulgatus cell
suspension (n = 4). The B. vulgatus cell suspensions contained 2 × 109 CFU/mL. At 24 h post-association, mice were challenged with V. cholerae
infection (5 × 108 CFU) for 24 h. b Viable V. cholerae cells in SI, colon, or fecal pellets were enumerated and presented in log-scale. **P < 0.001
versus bacterial CFU in the control and heat-inactivated Bv groups. c Schematic diagram of the experimental procedure. Five-day-old infant mice
(n = 4 or 6 per group) ingested 50 μL PBS (n = 6) or B. vulgatus cell suspension (n = 4). The B. vulgatus cell suspensions contained 1 × 109 CFU/
mL. At 12 h post-association, mice were challenged with V. cholerae infection (1 × 108 CFU) for 12 h. d Viable V. cholerae cells in intestinal extract
were enumerated and presented in log-scale. **P < 0.05 versus bacterial CFU in the control group. At the end of the infection period, fluid
accumulation ratio was calculated by the equation of (intestine weight)/[(total body weight)-(intestine weight)]. *P < 0.05 versus the
control group
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were selected and presented as dominant metabolites
in the CL-treated group (Table 1, bottom portion).
Relative quantities of those molecules were either non-
detectable (compounds 14, 21, 23, and 27) or consider-
ably smaller in the control SPF group. These results
further support the notion that distinct profile change
occurred in response to CL treatment. We next exam-
ined how V. cholerae growth is controlled by each of
these major compounds. Of the 27 listed compounds,
17 were selected based on the availability and we
monitored V. cholerae in vitro growth in M9 media
supplemented with each metabolite. Growth curve
experiments shown in Fig. 6 were conducted to reveal
compounds that can inhibit V. cholerae growth. M9
media used in this particular set of growth experiments
contain 0.4% glucose as primary carbon source, thereby
enabling us to monitor whether the extraneously added
metabolite promotes or inhibits V. cholerae growth. Seven
metabolites shown in panels K~Q clearly inhibited V.
cholerae growth. Importantly, these compounds were
present in the largest quantities in regular SPF mouse
intestines, but either absent or barely detectable in CL-
treated mouse intestines (Table 1). Prominent growth
promotion was observed when the culture medium in-
cluded NAG (Fig. 6b), a metabolite detected at sufficiently
high level in CL-treated mice. Supplementation with urea
(Fig. 6a), glucaric acid (Fig. 6f), putrescine (Fig. 6i), or
fumaric acid (Fig. 6j) resulted in a slight growth stimula-
tion, especially during the early stage of growth. Again,
these metabolites were detected more abundantly in CL-
treated mice, than in the SPF control mice (Table 1).
When N16961 growth was assessed in M9 media with an
indicated metabolite as the sole carbon source, each
metabolite’s ability to stimulate V. cholerae growth was
clearly demonstrated (Fig. 7). Consistent with result
shown in Fig. 6b, NAG was most potent in stimulating V.
Fig. 5 Heat map constructed from hierarchical cluster analysis (HCA) of cecal metabolites. Metabolites (n = 273) that exhibit similar detection
patterns in four samples are clustered, and the distance between clusters is shown as a tree diagram. The degree of red or green color indicates
a larger or smaller amount of a given metabolite. Columns 1 and 2 display metabolome profiles of regular SPF mice, while 3 and 4 shows those
of CL-treated groups. Columns 2 and 4 are metabolome profiles after V. cholerae infection in each group
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cholerae growth, with OD600 values reaching ~ 1.05
(Fig. 7b). Next to NAG, gluconic acid (Fig. 7d) and
gluconolactone (Fig. 7g) were effective at promoting V.
cholerae growth. As expected, seven inhibitory metabo-
lites (cholic acid, butyric acid, isobutyric acid, propionic
acid, valeric acid, isovaleric acid, and trimethylamine) still
prevented growth of V. cholerae (Fig. 7k–q). Together,
these results illustrate that CL-induced changes in the
host intestine are clearly reflected on metabolite level and
such major alterations of metabolomic profiles signifi-
cantly affect V. cholerae intestinal growth.
CL-treated adult mice can serve as a model for
investigating V. cholerae pathogenesis
Our results demonstrate that infection-induced pheno-
types, such as intestinal colonization and fluid accu-
mulation, are clearly observed in CL-pretreated adult
mice. Therefore, we finally examined whether or not
CL-treated mice can be utilized as a model to delineate
V. cholerae infection. To address this issue, two groups
of mice were infected with 1:1 mixture of N16961 and
its ΔtcpA mutant, a well-characterized V. cholerae mu-
tant defective in colonizing the intestine [40]. We then
compared colonization capabilities of these two strains
by calculating the competitive index. In this particular
set of experiments, fluid accumulation and bacterial
colonization were again substantially increased in CL-
treated mice, but not in PBS-treated control group
(Additional file 3: Figure S3). V. cholerae cells were
completely eliminated in three out of six mice in
control group (red arrow lines, Fig. 8a). Importantly,
ΔtcpA mutant exhibited significantly reduced colonization
capabilities, in comparison to WT N16961 (Fig. 8b). The
average values of the competitive indices (ΔtcpA/WT)
were ~ 0.29 and ~ 0.28 in the small intestine and cecum of
CL-treated mice, respectively. In contrast, meaningful
differences in colonization capabilities between two
strains were not detected, when untreated adult mice
were used (Fig. 8b). These results suggest that CL
pretreatment not only induces active bacterial
colonization but also creates a valuable environment
we can exploit to better understand the pathogenesis
of V. cholerae.
Discussion
A long-standing unresolved question in cholera re-
search is how V. cholerae has evolved as a human-spe-
cific pathogen in nature. It has been of particular
Table 1 Metabolites found to be dominant in regular SPF and CL-treated mouse intestines and their impacts on V. cholerae growth
Twenty-seven metabolites that were present exclusively in either group were selected among 273 compounds. Metabolites detected most abundantly in the
control group (No.1~13) or in the CL-treated group (No.14~27) are listed in the order of quantity. The growth-inhibiting or growth-promoting capability of a given
metabolite is displayed semi-qualitatively with a minus (−) or plus (+) sign, respectively. For example, “+” indicates a metabolite with mild growth-promoting
capability, whereas “---” indicates that the metabolite induced strong growth suppression. ND not detected, NT not tested, m/z mass-to-charge ratio, MT migration
time, RT retention time, Vc Vibrio cholerae. Relative quantity of a metabolite is calculated by the equation: (peak area of the metabolite)/(peak areas of internal
standards × sample amount). Peaks are assigned based on the signal-to-noise ratio (S/N) of 3 or above.
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interest that GM1 ganglioside, a lipid molecule that
binds to CT, is present not only on human intestinal
epithelium but also mouse intestinal epithelium [41, 42].
This notion suggests that CT, the most important viru-
lence determinant in V. cholerae, should also be active
in mouse intestine. However, adult mice are naturally
resistant to V. cholerae infection. We hypothesized that
understanding compositional differences between hu-
man and mouse intestinal microbiotas would help
address this important issue of host tropism.
Our 16S rRNA gene sequencing data (Figs. 1 and 3)
show that approximately 80% of the C57BL/6 mouse
gut microbiota belongs to the Bacteroidetes phylum.
Virtually complete elimination of the phylum induced
by CL treatment is essential for infecting the murine
host with V. cholerae. However, for our findings to be
clinically relevant, it needs to be first established that
the mouse gut microbiome is, to a sufficient degree,
reflective of the human gut microbiome. Previous
studies have reported predominantly high relative
abundances of the Bacteroidetes phylum in both mouse
and human gut microbiomes [43–46]. Furthermore,
there is evidence that B. vulgatus isolates from human
and other animal hosts are indistinguishable based on
their 16S rRNA gene sequences [47], suggesting phylo-
genetic proximity between mouse- and human-gut
resident B. vulgatus strains. Nonetheless, the compos-
ition of a gut microbiome does not necessarily reflect
its functional capacity [46]. Additionally, even though
the mouse gut microbiome closely resembles that of
humans at the phylum level, the similarity dissipates
on lower taxonomic levels, as families and genera that
comprise the predominant Bacteroidetes phylum are
quite different between mice and humans [44]. To
Fig. 6 Effects of selected metabolites on the inhibition of V. cholerae growth in vitro. N16961, a 7th pandemic V. cholerae strain, was grown in the
presence of indicated metabolites in M9 media. A total of 17 metabolites were tested. Medium pH was neutralized by adding NaOH or HCl,
when necessary. OD600 values were measured to monitor bacterial growth every 2 h. M9 media contains 0.4% glucose as a primary carbon
source. Lines in gray show bacterial growth in M9+glucose (M9G), while black lines indicate bacterial growth in M9G supplemented with
indicated metabolites. Cholic acid (panel k), Butyric acid (panel l), Isobutyric acid (panel m), Propionic acid (panel n), Valeric acid (panel o),
Isovaleric acid (panel p), and Trimethylamine (panel q) are highly capable of inhibiting N16961 growth
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compensate for such limitations, we have demonstrated
that our key findings are reproduced when GF mice are
mono-associated with B. vulgatus and infected with V.
cholerae (Fig. 4a, b). Given such considerations, it is likely
that the relative abundance of B. vulgatus is an important
determining factor for V. cholerae infectivity not only in
murine hosts but in humans as well. An important ques-
tion would be how abundantly B. vulgatus cells that share
similar functions with mouse isolates are present in
human intestine.
Based on our species-level population changes,
Escherichia coli explosively proliferated during CL
treatment and became the most dominant component
(Fig. 3). This finding suggests that elevated susceptibility
to V. cholerae infection in CL-pretreated mouse could
also be due to the presence of E. coli cells in large
quantity. In line with this notion, an E. coli strain with
robust catalase activity was found to stimulate
enhanced V. cholerae intestinal colonization in neo-
natal mice [1]. In the same work, increased V. cholerae
colonization occurred in VAN-treated adult mice [1].
In the current study, however, cholera-like symptoms
including fluid accumulation in the small intestine and
production of watery fecal matter were not observed in
the VAN-treated group (Fig. 1k). We therefore
conclude that the loss of B. vulgatus is a much more
critical determinant over increased E. coli for host sus-
ceptibility to V. cholerae infection.
In the present study, we found that CL treatment increases
V. cholerae infectivity in the normally resistant adult mice.
Previous studies have reported that antibiotic administration
triggers dysbiosis in the gut microbiota [48, 49], and such
perturbations lead to suppression of host resistance against
various enteropathogenic infections. Since CL treatment
Fig. 7 Effects of selected metabolites on the stimulation of V. cholerae growth in vitro. Bacterial growth was conducted as described in Fig. 6. To
examine growth-stimulating capabilities of metabolites, M9 media lacking in glucose was used in experiments. Lines in gray show bacterial
growth in M9 with no carbon source, while black lines indicate bacterial growth in M9 supplemented with indicated metabolites. Compounds
shown in purple font promoted bacterial growth, albeit to varying degrees. The degree of growth-promoting capability of a given metabolite is
displayed semi-qualitatively with “+++”, “++”, or “+” in Table 1. “+++” indicates the metabolite with the strongest growth-promoting capability,
while the “+” means that the metabolite induced a mild growth promotion
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results in significant perturbation of the gut microbiome, it is
conceivable that this model would demonstrate increased
susceptibility to infections by other enteric pathogens such
as Salmonella enterica serovar Typhimurium, Citrobacter
rodentium, and Clostridium difficile. However, for the afore-
mentioned enteric pathogens, there already exists a well-
established adult mouse model [50, 51]. Here, we suggest a
simple and convenient animal model to study V. cholerae in-
fection. The adult mouse model treated with oral CL consist-
ently exhibited cholera-like symptoms. Out of the several
already existing animal models for cholera research, the
suckling mouse model is considered to be a descriptive
model that manifests the cholera-characteristic watery diar-
rhea. However, the model is not adequate for use in vaccine
research, because suckling mice have yet to develop adaptive
immunity [52]. Moreover, the susceptibility of suckling mice
to V. cholerae infection might be an artifact caused by their
immature immune system, although this idea has not yet
been fully verified. Therefore, an infection model using adult
mouse has been required for the purpose of unveiling the
pathophysiological mechanisms that V. cholerae employs to
induce cholera in the host intestine [53]. However, intestinal
fluid secretion and continuous colonization of V. cholerae do
not readily occur in adult mice harboring intact gut micro-
flora [54, 55]. For this reason, the ligated ileal loop model
that involves surgical manipulation of the animal’s intestine
has been proposed as an alternative [56]. Our CL-induced
adult mouse model, which can be established by a simple
treatment, clearly reproduces typical cholera symptoms ob-
served in humans, such as the severe watery diarrhea,
extensive fluid accumulation, and V. cholerae colonization
within the intestinal mucus layer. Furthermore, in our model,
CT has been detected in the intestinal fluid, at a level suffi-
cient to elicit intestinal fluid secretion (Fig. 2c). In addition,
the competitive index of ΔtcpA/WT showed that TCP, a
verified colonization factor of V. cholerae in human intestine
[57, 58], is also essential for the induction of illness in adult
mice (Fig. 8). To date, the importance of TCP has been ex-
plored only in infant rabbits [53] and infant mice [59].
Host-derived mucus glycan is a nutrient source uti-
lized exclusively by the gut microbiota. Considering
the microbial competition for nutritional resources in
the intestinal tract and constant release of glycan into
the lumen by epithelial cell turnover [60–62], the
ability of select microbes to nutritionally exploit the
glycans confers a conceivable advantage toward their
survival and proliferation. A large proportion of glycan
structures consist of N-acetyl amino sugars, such as N-acet-
ylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc,
NAG), and N-acetylneuraminic acid (Neu5Ac, NANA).
Monosaccharides are produced as the result of mucin
glycans being catabolized by the gut microbial species
equipped with glycosidase genes. Bacteroides has
evolved to express glycosidase genes which allow them
to perform mucin degradation to full completion, and
thus become well-adapted to thrive in the intestine
[61–63]. The anaerobes that belong to the Bacteroi-
detes phylum and Clostridia produce pyruvate through
glycolysis [61, 64]. Under the anoxic conditions of the
intestine, the gut microbiota obtains additional energy
Fig. 8 A V. cholerae ΔtcpA mutant is defective in colonizing the intestine of CL-treated adult mice. N16961 and its ΔtcpA mutant grown in LB
were harvested and mixed at 1:1 ratio. A mixture of 1 × 109 CFU was inoculated via oral gavage into PBS-treated (control) or CL-treated mice
(n = 6 per group). At 24 h post-infection, mice were sacrificed to measure bacterial colonization. a Viable cell numbers of V. cholerae cells (both
N16961 and the ΔtcpA mutant). Aliquots of lysates (small intestine or cecum) were serially diluted for V. cholerae CFU counting on LB agar
supplemented with 200 μg/mL SM. Values are displayed on a log scale as mean ± SEM for each group. *P < 0.05 versus bacterial CFUs detected
in the control group. In three out of six mice in the control group, no V. cholerae cells were recovered in the small intestine or cecum (red
arrows). b The competitive index represents the ratio of ΔtcpA mutant to N16961 recovered after infection either in the small intestine or cecum
in each mouse after infection. *P < 0.05 versus the competitive index obtained from infection with no CL treatment
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by exploiting the pyruvate through anaerobic catabol-
ism. Predominant end products of the anaerobic
fermentation are short-chain fatty acids (SCFAs), such
as propionic acid, butyric acid, and valeric acid [61].
In this study, the dramatic changes in the cecal
metabolomes of CL-treated mice strongly correlate
with the compositional shift of the microbiota. Deple-
tion of SCFAs and relatively high occurrence of amino
sugars in the ceca of CL-treated mice indicate that
catabolism of mucin glycan, a proliferation strategy for
microbes belonging to the Bacteroidetes phylum, be-
came inactive upon CL treatment.
Utilization of the host glycan is also important for
the invasion of V. cholerae into the host intestine.
When the pathogen enters the intestinal tract, the next
strategy for its proliferation is to colonize the epithelial
cells covered with a viscous layer of mucus. V. cholerae
effectively responds to the mucus glycan and catabolize
the polysaccharides to acquire competitive advantage
in host intestine [65–68]. Glucosamine-6-phosphate
(GlcNP-6), a common intermediate molecule shared
between the catabolic pathways of GlcNAc and
Neu5Ac, was reported to be indispensable for V.
cholerae motility [68]. Chemotaxis mediated by motil-
ity toward the nutrient sources is important for
colonization and proliferation of V. cholerae [68].
Consistent with this notion, depletion of sialic acid
(Neu5Ac) transporters (encoded in VC1777-1779)
attenuates colonization [69]. During this process, V.
cholerae needs to overcome a number of challenges
such as acid stress, antimicrobial peptides, host im-
mune response, and SCFAs [64, 66, 68]. The reduction
of intestinal SCFAs in patients with diarrhea and
recovery of normal SCFA levels after conventional
treatment support that the SCFAs could be a contrib-
uting factor to eubiosis of the intestinal microbiota
[70]. In general, SCFAs are considered to be an effect-
ive barrier against pathogenic invasion, although some
enteric pathogens exploit SCFAs to sense their sur-
roundings and to decide whether or not to express
their arsenal of virulence factors [71].
Our results suggest that catabolism of N-acetyl
amino sugars and subsequent accumulation of SCFAs
in the distal intestine are largely managed by specific
gut microbiota (Fig. 3). Elimination of the anaerobic
Bacteroides and Clostridium genera caused by CL
treatment results in drastic changes of intestinal me-
tabolites as summarized in Fig. 9. Especially, propionic
and butyric acid mainly produced by Bacteroides and
Clostridium, respectively, are dramatically reduced
after CL treatment, thus leaving a variety of metabo-
lites (NAG, NANA, gluconate, gluconolactone, etc.)
Fig. 9 Summary of CL-induced microbiota composition changes and its impact on host susceptibility to V. cholerae infection. A remarkable shift
in commensal microbiota population occurs in response to treatment with CL. Under normal condition, B. vulgatus, and to a lesser degree, also
Clostridium spp. metabolize mucin glycan and accumulation of metabolites including SCFAs that suppress V. cholerae intestinal growth ensues.
Metabolites that increased in quantities upon CL treatment, such as amino sugars, potentiate V. cholerae intestinal growth
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available for utilization by V. cholerae (Fig. 9). Of
particular note, gluconate and its intermediate metabo-
lites were found to enhance the colonization and
virulence of V. cholerae within the intestine [72]. In
the perturbed intestinal environment, V. cholerae read-
ily acquires nutrient sources as there is no competition
with the host glycan-degrading and thus SCFA-producing
gut microbiota (mainly Bacteroides and Clostridium)
genera.
Conclusions
In conclusion, we identified a commensal bacterial
species, B. vulgatus, that plays a significant role in
inhibiting V. cholerae colonization in the adult mouse
intestine. Moreover, we propose a simple antibiotic-
treated mouse model to delineate V. cholerae infection,
which might prove a useful tool for cholera vaccine re-
search. We hope that the results presented in the
present study will stimulate future investigations to
better understand the in vivo probiotic function of B.
vulgatus against V. cholerae infection and to devise
better strategies for tackling this virulent and clinically
important human pathogen.
Methods
Bacterial strains and growth condition
Vibrio cholerae O1 serotype N16961 was used as a
model pathogen in all experiments [73]. N16961 was
routinely grown in Luria-Bertani (LB) broth (10 g
NaCl, 10 g tryptone, and 5 g yeast extract per L) or on
LB agar plates (15 g agar per L) at 37 °C under aerobic
condition. In order to selectively isolate N16961 from
feces, SI, cecum, and colon, we used streptomycin
(Duchefa) at a 200 μg/mL concentration. Another se-
lective medium used to isolate V. cholerae from intes-
tinal contents was thiosulfate-citrate-bile salt-sucrose
(TCBS) medium. For enumeration of intestinal V. cho-
lerae loads, mouse intestines were manually extracted
from infected animals. The SIs, ceca, and colons were
then homogenized in PBS (Sigma-Aldrich) and centri-
fuged at 1000 rpm for 1 min. The supernatants were
serially diluted in PBS, and spotted on an LB agar plate
containing streptomycin. B. vulgatus strains were
isolated from C57BL/6 mouse intestines using Bacter-
oides Bile Esculin (KisanBio, Korea) agar plates. Subse-
quently, B. vulgatus strains were cultivated on Gifu
Anaerobic Media (GAM) broth (KisanBio, Korea) in an
anaerobic chamber maintained at 90% N2, 5% CO2,
and 5% H2. All anaerobic culture media were
deoxygenated for at least 24 h prior to usage. RAPD
analysis was performed using six different B. vulgatus
colonies recovered independently from two different
CL-treated mice, following procedures described else-
where [1].
Mouse husbandry and antibiotic treatment
Experiments were performed using both SPF and GF
mice in a C57BL/6 genetic background. SPF mice were
obtained from Orient Bio (Sungnam, Korea), and GF
mice were generated by the Yonsei University College of
Medicine GF mouse facility. Mice were provided sterile
water and autoclaved food. GF status was confirmed by
negative microbial growth in mouse feces. GF mice were
bred and housed in flexible-film isolators (Class Bio-
logically Clean Ltd., Madison, WI). When necessary, GF
mice were transferred to isocages (Tecniplast Inc., Italy)
for experimental grouping. All mouse experiments were
conducted according to the guidelines provided by the
Department of Animal Resources of Yonsei Biomedical
Research Institute. The Committee on the Ethics of
Animal Experiments at Yonsei University College of
Medicine approved this study (Permit numbers, 2017-
0210 and 2018-0250).
For the antibiotic treatment presented in Fig. 1, 8- to
9-week-old C57BL/6 female mice were administered
either SM (1 mg), VAN (250 μg), and CL (1 mg), or
PBS by oral gavage once a day for 5 days. The dosage
of the antibiotics was chosen to induce dysbiosis but
not complete elimination of commensal species of the
gut microbiota. Each oral gavage treatment did not ex-
ceed 100 μl. For the antibiotic treatment shown in
Additional file 2: Figure S2, mice were treated with a
single dose of CL (10 mg).
V. cholerae infection and GF mouse manipulation
V. cholerae cells grown aerobically overnight at 37 °C
were diluted 100-fold to inoculate fresh LB broth
medium. The sub-cultured broth was incubated in a
shaking incubator at 37 °C for 4 h. Finally, V. cholerae
cells were centrifuged at 13,000 rpm for 10 min, and
the resulting pellet was suspended in sterile PBS to the
concentration of 1010 CFU per mL. For infection, 8- to
9-week-old mice were orally infected with 50 μl of V.
cholerae cell suspension containing approximately 5 ×
108 CFU of V. cholerae cells. The fluid accumulation
ratio was calculated by using the equation (intestine
weight) / (total body weight-intestine weight). CT level
was quantified by CT ELISA [38]. To enumerate V.
cholerae cells in mouse feces, fecal pellets were physic-
ally disrupted to homogeneity, and fecal suspensions
were serially diluted for CFU counting. Shortly after
euthanasia, SI, cecum, and colon samples were manu-
ally extracted from each mouse and homogenized in 5
mL of PBS. The sample homogenates were centrifuged
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at low speed for remnant tissue removal, and the
resulting supernatant was used for CFU counting.
FMT was performed to transplant the antibiotic-
treated gut microbiota into GF mice. SPF mice were
treated either with CL or PBS as per the procedure
described above, and fresh feces were collected 24 h
post-antibiotic treatment. In each antibiotic-treated
and control group, there were three mice, and two
fecal pellets were collected from each mouse. The fecal
pellets collected were pooled per group and suspended
in 600 μl of PBS. The suspension was quick-centri-
fuged to remove the debris, and the resulting
supernatants were orally administered. Each GF mouse
received 50 μl of FMT solution by oral gavage. For B.
vulgatus mono-association, B. vulgatus was first seeded
with thawed stock and passaged at least twice and less
than 4 times for maximum viability. B. vulgatus cells
were grown in GAM broth under anaerobic conditions.
The cultured B. vulgatus cells were resuspended in
PBS, and 108 CFU cells were delivered orogastrically to
GF mice. Infant mouse infection was performed
following procedures described previously [39].
Competitive index assay
To proceed with the competitive index assay, lacZ-
negative wild-type strain N16961 and lacZ-positive
ΔtcpA were cultured as per the aforementioned V. cho-
lerae culture protocol. Sub-cultured wild-type and
ΔtcpA cells were centrifuged at 13,000 rpm for 2 min
and then resuspended in PBS. Each strain was mixed
at a 1:1 ratio, and 100 μl of the prepared mixture (total
109 CFU) was administered to 8- to 9-week-old female
C57BL/6 mice (either untreated or CL-treated) by oral
gavage. Each mouse was infected with 5 × 108 CFU of
each strain.
Amplicon sequencing for microbiome profiling
The extraction method for bacterial DNA was per-
formed using a PowerMax Soil DNA Isolation Kit (MO
BIO). Each sequenced sample was prepared according
to the Illumina 16S Metagenomic Sequencing Library
protocols to amplify the V3 and V4 regions (519F-
806R). The DNA quality was measured by PicoGreen
and Nanodrop. Input gDNA (10 ng) was PCR ampli-
fied. The barcoded fusion primer sequences used for
amplifications were as follows: 341F: 5′-CCTACG
GGNGGCWGCAG, and 806R: 5′-GACTACHVGGG-
TATCTAATCC. The final purified product was then
quantified using qPCR according to the qPCR Quanti-
fication Protocol Guide (KAPA Library Quantification
kits for Illumina Sequencing platforms) and qualified
using a LabChip GX HT DNA High Sensitivity Kit
(PerkinElmer, MA, USA). Paired-end (2 × 300 bp)
sequencing was performed by Macrogen using the
MiSeq™ platform (Illumina, San Diego, CA, USA). For
species identification, sequenced reads were aligned
using blast and NCBI 16S microbial database (version
downloaded 2018.01.14). Taxonomy information was
assigned only to OTUs that met both query coverage
> 85% and identity percent > 85%. OTUs that did not
meet these two criteria were left unassigned. In
general, microbial species was identified with ~ 99%
identity with a reference sequence.
Metabolite extraction
For extracting ionic metabolites, approximately 50 mg
of cecal contents was dissolved in MilliQ water
containing internal standards (H3304-1002, Human
Metabolome Technologies (HMT), Tsuruoka, Yama-
gata, Japan) at a ratio of 1:9 (w/v). After centrifugation,
the supernatant was centrifugally filtered through a
Millipore 5000-Da cutoff filter (UltrafreeMC-PLHCC,
HMT) to remove macromolecules (9100×g, 4 °C, 60 min)
for subsequent analysis with capillary electrophoresis
time-of-flight mass spectrometry (CE-TOFMS).
Metabolome analysis
Metabolome analysis was conducted at HMT using the
Basic Scan package with CE-TOFMS for ionic metabo-
lites, based on the methods described previously [74, 75].
Briefly, CE-TOFMS analysis was carried out using an
Agilent CE capillary electrophoresis system equipped
with an Agilent 6210 time-of-flight mass spectrometer,
Agilent 1100 isocratic HPLC pump, Agilent G1603A CE-
MS adapter kit, and Agilent G1607A CE-ESI-MS sprayer
kit (Agilent Technologies, Waldbronn, Germany). The
systems were controlled by Agilent G2201AA Chem-
Station software version B.03.01 for CE (Agilent Tech-
nologies) and connected by a fused silica capillary (50
μm i.d.×80 cm total length) with commercial electro-
phoresis buffer (H3301-1001 and H3302-1021 for
cation and anion analyses, respectively, HMT) as the
electrolyte. The spectrometer was scanned from m/z
50 to 1000 [74]. Peaks were extracted using the
automatic integration software MasterHands (Keio
University, Tsuruoka, Yamagata, Japan) to obtain peak
information including m/z, peak area, and migration
time (MT) for CE-TOFMS analysis [76]. Signal peaks
corresponding to isotopomers, adduct ions, and other
product ions of known metabolites were excluded, and
remaining peaks were annotated according to the
HMT metabolite database based on m/z values with
the MTs determined by TOFMS. Areas of the anno-
tated peaks were then normalized based on internal
standard levels and sample amounts to obtain relative
levels of each metabolite. Hierarchical cluster analysis
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(HCA) was performed using the proprietary software
supplied by HMT, PeakStat.
V. cholerae in vitro growth curve experiments
N16961 was grown in M9 media supplemented with 17
metabolites at 20 mM each, with the exception of N-
acetylglucosamine (GluNAc), N-acetylneuraminic acid
(NANA), glucaric acid, gluconolactone, mannosamine,
and cholic acid. These metabolites were added at con-
centrations of 4, 1, 4, 10, 1, and 0.2 mM, respectively.
N16961 growth was monitored by measuring OD600
values spectrophotometrically. To examine growth-inhi-
biting capabilities of the metabolites, N16961 was grown
in M9 plus 0.4% glucose. However, M9 salt without glu-
cose was used to assess the capabilities of the metabo-
lites to promote the growth of V. cholerae.
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Unpaired Student’s t test was used to
determine whether differences between groups were
significant. A p value < 0.05 was considered to indicate
statistical significance. All experiments were repeated
for reproducibility.
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